{"id":5593,"date":"2023-09-04T03:11:04","date_gmt":"2023-09-04T03:11:04","guid":{"rendered":"https:\/\/cm.vastapps.dev\/tcia-collection\/exact\/"},"modified":"2023-09-13T11:58:56","modified_gmt":"2023-09-13T11:58:56","slug":"exact","status":"publish","type":"tcia_collection","link":"https:\/\/cm.vastapps.dev\/tcia-collection\/exact\/","title":{"rendered":"EXACT"},"featured_media":0,"template":"","citation-tax":[],"cancer_types":["Anal Cancer"],"citations":[4468,2925],"collection_doi":"10.7937\/2023.na2x-j031","collection_download_info":"This is a\u00a0limited access\u00a0data set. If you are an investigator on this project, to request access to ExACT data, please contact\u00a0help@cancerimagingarchive.net<\/a>.\n\nClick the Versions tab for more info about data releases.","collection_downloads":[5032,5033,5034],"full_export":"

Summary<\/h1>

Accurate pre-therapeutic imaging of the tumour and regional lymph nodes, is - in addition to clinical examination and assessment for distant metastases -essential for prognostication and guiding treatment. Nodal staging has been validated as an important independent prognostic factor [EORTC22861; RTOG9811] and the nodal stage as well as the precise location of involved lymph nodes (mesorectum, presacral space, internal iliac lymph nodes, external iliac lymph nodes, ischiorectal fossa, inguinal lymph nodes) informs the planning of radiotherapy treatment especially when using more conformal techniques such as intensity modulated radiotherapy. It is therefore essential to optimize and standardize pre-treatment imaging to provide accurate and reproducible information to guide treatment decision, development of radiotherapy atlases and clinical trial design.<\/p>

Whereas there currently exist a lack of consensus as to which staging modality should be considered as the gold standard for local staging of the tumour (T) and detection of lymph node involvement (N), the use of multi-parametric Magnetic Resonance Imaging (MRI) of the pelvis has been endorsed by international guidelines (NCCN, ESMO\/ESTRO).<\/p>

An expert panel of radiologist and radiation oncologists with expertise in anal cancer diagnosis and treatment identified by the Anal Staging Subgroup of the International Rare Cancer Incentive (IRCI) will be invited to participate. The panelists will be assigned into groups based on the geographical location and local practice. Each panelist will be provided with access to a series of anonymized MRI datasets of patients with newly diagnosed anal cancer and asked to provide a TNM stage as well as to identify sites of involved nodes (using a standardised proforma \u2013 Appendix1).\u00a0 Each case was selected for the presence of MRI sequences like these:<\/p>